Atropos Health

Atropos Health builds software that converts real-world clinical data, primarily from electronic medical records, into methodologically documented observational studies that answer specific clinical questions. Its core technology is GENEVA OS, described as an operating system for rapid healthcare evidence generation across a network of real-world data sources. Queries run against a network of de-identified patient records; the system executes statistical analyses and formats results into a standardized observational study report the company calls a Prognostogram. The company positions this against what it terms the "evidence gap" — its site states only 14% of daily medical decisions are backed by high-quality evidence, and it cites a 2017 BMJ study finding 18% of primary care clinical recommendations rest on current evidence, along with the exclusion of much of the population from clinical trials.

Products include ChatRWD, a chat-based generative-AI interface launched in beta in Q4 2023 that produces full observational studies on real-world data, built as an LLM-independent framework intended to limit hallucination risk and preserve institutional LLM security. Other named assets include the Atropos Evidence Network of partner healthcare institutions and data sources, and Alexandria, a body of medical evidence that the company states contains 33 million precision Evidence-Based Findings, with plans to grow to more than two billion studies in 2026. An Atropos Evidence Agent MCP has been published on the Databricks Marketplace.

For health systems, the company markets applications across pharmacy and formulary program design, quality and operations, value-based care and population health, graduate medical education, point-of-care decision support, and academic publishing support, stating timelines of under two weeks from idea to abstract or poster and two months to manuscript. Reported customer-side outcomes cited on its site include $547K in drug cost savings from comparative effectiveness studies, $1.2M in research cost savings, and $1.62M in length-of-stay savings.

Founding story

Atropos Health was founded in 2019 by Brigham Hyde, Nigam Shah and Saurabh Gombar as a spin-out of the "Green Button" project at Stanford University, which used dormant EMR data to inform clinical decision-making.

Business model

Atropos Health sells access to its evidence-generation platform, tools and data network to healthcare provider organizations and life sciences companies, combining cloud software with a physician-centered service that fulfills clinical informatics consult requests and delivers study reports.

Commercial contracts with healthcare institutions and life sciences organizations for platform access and evidence generation; the company directs prospects to a sales team rather than publishing pricing.

Traction

The company reports more than 10,000 clinical questions converted into studies for clients, over 50 peer-reviewed publications including in Cell and NEJM Catalyst with a stated 100% publication success rate, and $100M in client-reported savings. Its evidence network is described as covering hundreds of millions of de-identified records, with more than 200 million unique patients cited in May 2024. Named users and partners include Stanford Health Care, Mayo Clinic Platform, Arcadia, Emory Healthcare, and Janssen Research & Development.

Latest developments

Following the May 2024 Series B, the company expanded its partnership with Databricks by launching the Atropos Evidence Agent MCP on the Databricks Marketplace, and announced that its Alexandria evidence base reached 33 million precision Evidence-Based Findings with a target of more than two billion studies in 2026. It also presented a study on the association between semaglutide and bone fracture risk in type 2 diabetes at an Endocrine Society meeting.